Percutaneous Left Atrial Appendage Closure for Cerebrovascular Accident Prevention: rationale, indications, Technical aspects, Clinical Results and Future Perspective

References

• Go AS , HylekEM, PhilipsKAet al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 285, 2370–2375 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf PA , AbbottRD, KannelWB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 22, 983–988 (1991).
   PubMed Web of Science ®Google Scholar
• Coppens M , EikelboomJW, HartRGet al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur. Heart J., 34, 170–176 (2013).
   PubMed Web of Science ®Google Scholar
• Kirchhof P , BenussiS, KotechaDet al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 18, 1609–1678 (2016).
   PubMed Web of Science ®Google Scholar
• Gage BF , WatermanAD, ShannonWet al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA, 285, 2864–2870 (2001).
   PubMed Web of Science ®Google Scholar
• Pisters R , LaneDA, NieuwlaatR, de VosCB, CrijnsHJ, LipGY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 138, 1093–1100 (2010).
   PubMed Web of Science ®Google Scholar
• Olesen JB , LipGY, LindhardsenJet al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb. Haemost., 106, 739–749 (2011).
   PubMed Web of Science ®Google Scholar
• Friberg L , RosenqvistM, LipGY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur. Heart J., 33, 1500–1510 (2012).
   PubMed Web of Science ®Google Scholar
• Ruff CT , GiuglianoRP, BraunwaldEet al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet, 383, 955–962 (2014).
   PubMed Web of Science ®Google Scholar
• Hart RG , PearceLA, AguilarMI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med., 146, 857–867 (2007).
   PubMed Web of Science ®Google Scholar
• Go AS , HylekEM, ChangYet al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA, 290, 2685–2692 (2003).
   PubMed Web of Science ®Google Scholar
• Singer DE , ChangY, FangMCet al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann. Intern. Med., 151, 297–305 (2009).
   PubMed Web of Science ®Google Scholar
• Reynolds MW , FahrbachK, HauchOet al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest, 126, 1938–1945 (2004).
   PubMed Web of Science ®Google Scholar
• Connolly SJ , EzekowitzMD, YusufSet al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 361, 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Patel MR , MahaffeyKW, GargJet al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 365, 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• Granger CB , AlexanderJH, McMurrayJJet al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 365, 981–992 (2011).
   PubMed Web of Science ®Google Scholar
• Giugliano RP , RuffCT, ENGAGE AF-TIMI 48 Investigatorset al. . Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 369, 2093–2104 (2013).
   PubMed Web of Science ®Google Scholar
• Chaudhary R , SharmaT, GargJet al. Direct oral anticoagulants: a review on the current role and scope of reversal agents. J. Thromb Thrombolysis., 49(2), 271–286 ( 2019).
   Web of Science ®Google Scholar
• Manning WJ , WeintraubRM, WaksmonskiCA. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann. Intern. Med., 123, 817–822 (1995).
   PubMed Web of Science ®Google Scholar
• Wang Y , DiBiase L, HortonRP, NguyenT, MorhantyP, NataleA. Left atrial appendage studied by computed tomography to help planning for appendage closure device placement. J. Cardiovasc. Electrophysiol., 21, 973–982 (2010).
   PubMed Web of Science ®Google Scholar
• Al-Saady NM , ObelOA, CammAJ. Left atrial appendage: structure, function and role in thromboembolism. Heart, 5, 547–554 (1999).
   Google Scholar
• Veinot JP , HarrityPJ, GentileF. Anatomy of the normal left atrial appendage: a quantitative study of age-related changes in 500 autopsy hearts: implications for echocardiographic examination. Circulation, 96, 3112–3115 (1997).
   PubMed Web of Science ®Google Scholar
• Di Biase L , SantangeliP, AnselminoMet al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J. Am. Coll. Cardiol., 60, 531–538 (2012).
   PubMed Web of Science ®Google Scholar
• January CT , WannLS, CalkinsHet al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol., 74, 104–132 (2019).
   PubMed Web of Science ®Google Scholar
• Ostermayer SH , ReismanM, KramerPHet al. “Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials”. J. Am. Coll. Cardiol., 46, 9–14 (2005).
   PubMed Web of Science ®Google Scholar
• Holmes DR , ReddyVY, PROTECT AFInvestigatorset al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet, 15, 534–542 (2009).
   Google Scholar
• Reddy VY , HolmesD, DoshiSK, NeuzilP, KarS. Safety of percutaneous left atrial appendage closure results from the WATCHMAN® left atrial appendage system for embolic protection in patients with AF (PROTECT AF) Clinical Trial and the Continued Access Registry. Circulation, 123, 417–424 (2011).
   PubMed Web of Science ®Google Scholar
• Reddy VY , SievertH, HalperinJet al. PROTECT AF steering committee and investigators, percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA, 312, 1988–1998 (2014).
   PubMed Web of Science ®Google Scholar
• Holmes DR , KarS, PriceMJet al. Prospective randomized evaluation of the WATCHMAN® left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J. Am. Coll. Cardiol., 64, 1–12 (2014).
   PubMed Web of Science ®Google Scholar
• Reddy VY , DoshiSK, PREVAILand PROTECT AF Investigatorset al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J. Am. Coll. Cardiol., 70, 2964–2975 (2017).
   PubMed Web of Science ®Google Scholar
• Holmes DR , DoshiSK, KarSet al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J. Am. Coll. Cardiol., 65, 2614–2623 (2015).
   PubMed Web of Science ®Google Scholar
• Boersma LV , InceH, EWOLUTION Investigatorset al. . Efficacy and safety of left atrial appendage closure with WATCHMAN® in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm, 14, 1302–1308 (2017).
   PubMed Web of Science ®Google Scholar
• Reddy VY , Möbius-WinklerS, MillerMAet al. Left atrial appendage closure with the WATCHMAN® device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with WATCHMAN® left atrial appendage closure technology). J. Am. Coll. Cardiol., 61, 2551–2556 (2013).
   PubMed Web of Science ®Google Scholar
• Holmes DR , ReddyVY, BuchbinderMet al. The assessment of the WATCHMAN® device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial. Am. Heart J., 189, 68–74 (2017).
   PubMed Web of Science ®Google Scholar
• FDA Approval for WATCHMAN® Device . http://www.accessdata.fda.gov/cdrh_docs/pdf13/P130013a.pdf
   Google Scholar
• Viles-Gonzalez JF , KarS, DouglasPet al. The clinical impact of incomplete left atrial appendage closure with the WATCHMAN® device in patients with atrial fibrillation: a PROTECT AF (percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation) substudy. J. Am. Coll. Cardiol., 59, 923–929 (2012).
   PubMed Web of Science ®Google Scholar
• Mohanty S , GianniC, TrivediCet al. Risk of thromboembolic events after percutaneous left atrial appendage ligation in patients with atrial fibrillation: long-term results of a multicenter study. Heart Rhythm, 17, 175–181 (2020).
   PubMed Web of Science ®Google Scholar
• Schwartz RS , HolmesDR, Van TasselRAet al. Left atrial appendage obliteration: mechanisms of healing and intracardiac integration. J. Am. Coll. Cardiol. Intv., 3, 870–877 (2010).
   Google Scholar
• Saw J , Nielsen-KudskJE, BergmannMet al. Antithrombotic therapy and device-related thrombosis following endovascular left atrial appendage closure. J. Am. Coll. Cardiol. Intv., 12, 1067–1076 (2019).
   Google Scholar
• Søndergaard L , WongY-H, ReddyVYet al. Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN®. J. Am. Coll. Cardiol. Intv., 12, 1055–1063 (2019).
   Google Scholar
• Goitein O , FinkN, HayIet al. Cardiac CT angiography (CCTA) predicts left atrial appendage occluder device size and procedure outcome. Int. J. Cardiovasc. Imaging, 33, 739–747 (2017).
   PubMed Web of Science ®Google Scholar
• Goitein O , FinkN, GuettaVet al. Printed MDCT 3D models for prediction of left atrial appendage (LAA) occluder device size: a feasibility study. EuroIntervention, 13, e1076–1079 (2017).
   PubMed Web of Science ®Google Scholar
• US FDA . Executive summary P130013 prepared for the October 8, 2014 meeting of the Circulatory System Devices Panel (2015). https://webcache.googleusercontent.com/search?q=cache:9TH_oSwNBo8J
   Google Scholar
• Dörr M , NohturfftV, BrasierNet al. The WATCH AF Trial: SmartWATCHes for detection of atrial fibrillation. JACC Clin. Electrophysiol., 5, 199–208 (2019).
   PubMedGoogle Scholar
• Turakhia MP , DesaiM, HedlinHet al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart study. Am. Heart J., 207, 66–75 (2019).
   PubMed Web of Science ®Google Scholar
• Friedman DJ , PicciniJP, WangTet al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing concomitant cardiac surgery. JAMA, 319, 365–374 (2018).
   PubMed Web of Science ®Google Scholar
• Kuwata S , ViereckeJ, GloeklerS, MaisanoF, MeierB, NietlispachF. Left atrial appendage closure for “primary primary” prevention during percutaneous closure of septal defects in patients with large atria but no atrial fibrillation. Cardiol J., 25, 179–187 (2018).
   PubMed Web of Science ®Google Scholar
• Attia ZI , NoseworthyPA, Lopez-JimenezFet al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet, 394, 861–867 (2019).
   PubMed Web of Science ®Google Scholar
• Ma Z , ChengG, WangP, KhalighiB, KhalighiK. Clinical model for predicting warfarin sensitivity. Sci. Rep., 9, 12856 (2019).
   PubMed Web of Science ®Google Scholar
• Labovitz DL , ShafnerL, ReyesGil M, VirmaniD, HaninaA. Using artificial intelligence to reduce the risk of nonadherence in patients on anticoagulation therapy. Stroke, 48, 1416–1419 (2017).
   PubMed Web of Science ®Google Scholar